Slide 1: Q1 2025 Earnings Call Presentation
Q1 2025 Earnings Call Presentation May │ 2025 1
Slide 2: Disclaimer
Disclaimer This presentation has been prepared by Auna S.A. (“Auna” or the “Company”) solely for use at this presentation. This presentation is confidential to the recipient. Accordingly, any attempt to copy, summarize or distribute this presentation or any portion hereof in any form to any other pa
Slide 3: Today's Participants
Today’s Participants +30 +20 +25 Jesus Zamora Gisele Remy Lorenzo Massart Executive Chairman of the Board and Chief Financial Officer and Executive Vice President, Strategy and President Executive Vice President Equity Capital Markets • Member of the Board since 2008 and President • Chief Financial
Slide 4: 1Q 2025 Highlights
1Q 2025 Highlights “Despite the Adjusted EBITDA1 -8% YoY or +1% FXN2, with margin declining 1p.p. to 21.4% YoY quarter’s Reported results impacted by depreciation of PEN/MXN (-22%) and PEN/COP (-9%) YoY operational Consistent and strong performance in Peru resulting from our resilient and proven int
Slide 5: Adjusted EBITDA increases 1% FXN YoY; Peru continues to support results
Adjusted EBITDA increases 1% FXN YoY; Peru continues to support consolidated revenue and EBITDA Consolidated 1Q25 Revenue (S/) Adjusted EBITDA(1) (S/) 1,042 Mn 222 Mn -3% -8% +4% FXN YoY +1% FXN YoY Healthcare Services Oncosalud Peru Total Capacity Plan Oncology Oncology Bed Utilization Memberships
Slide 6: Q1 2025 Results by Segment
Q1 2025 Results by Segment qauna
Slide 7: Healthcare Services Mexico affected by temporary impact of new doctor/supplier standards
Healthcare Services Mexico affected by temporary impact of new doctor/supplier standards External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 26% of LTM Revenues 40% of LTM Adj. EBITDA 33.6% 34.7% 33.2% -4% (L.C) -5% (L.C) -21% -22% -10% (L.C) -6% (L.C) -13% -9% 104 308 93 268 81 243 1Q
Slide 8: Peruvian healthcare and Oncosalud segments continue to outperform our expectations
Peruvian healthcare and Oncosalud segments continue to outperform our expectations, achieving vertical integration efficiencies External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 41% of LTM Revenues 40% of LTM Adj. EBITDA +10% 20.4% 21.7% 22.1% +4% +19% 460 442 +6% 419 102 96 85 1Q’24
Slide 9: Colombia's revenues supported by risk sharing models and payor diversification
Colombia´s revenues supported by risk sharing models and payor diversification, offsetting effects of A/R provisions External Revenue1 (S/ Mn, %) Adj. EBITDA and margin1,2 (S/ Mn, %) 33% of LTM Revenues 22% of LTM Adj. EBITDA 18.6% 14.2% 12.2% +5% (L.C) -10% (L.C) -3% -17% -39% (L.C) -6% (L.C) -38%
Slide 10: Q1 2025 Consolidated Results
Q1 2025 Consolidated Results 10
Slide 11: Harvesting of vertical integration model in Peru and risk-sharing programs in Colombia
Harvesting of vertical integration model in Peru and risk-sharing programs in Colombia offset temporary YoY revenue decline in Mexico ▪ 1Q25 YoY revenues increased 10% in Peru and 5% in L.C. in Colombia, while Mexico declined 4% in L.C. ▪ Peru HC services grew on better mix and high complexity servi
Slide 12: Adjusted EBITDA -8% or +1% FXN YoY
Adjusted EBITDA1 -8% or +1% FXN YoY, mainly due to Mexico revenue decline and Colombia impairment provisions ▪ Adjusted EBITDA Margin1 of 21.4% in 1Q25 vs 22.4% in 1Q24 ▪ In Peru, Adjusted EBITDA1 delivered 19% YoY growth, with 1.7p.p. increase in Adjusted EBITDA Margin1 ▪ Impairment losses of S/10
Slide 13: Adjusted Net Income +1.5x YoY
Adjusted Net Income1 +1.5x YoY ▪ Fifth consecutive quarter of positive Adjusted Net Income Adjusted Net Income1 bridge: 1Q’24 vs 1Q’25 (S/ Mn) 1 13 55 53 22 Adjusted Adjusted EPS2 : 43 34 EPS2 : S/ 0.35 S/ 0.70 Adj. Net Operating Profit Fx variance Net interest Income tax Non-cash and Adj. Net Incom
Slide 14: End of period cash
End of period cash ▪ Cash decreased 15% vs. 4Q’24 ▪ Maintenance CAPEX at 4.5% of revenues Cash flow bridge (S/ Mn) Free Cash Flow 1 S/42 Net Cash Flows from Net Cash Flows used in Operations Investments Net Cash Flows in Financing S/106 S/(64) S/(78) 165 58 47 17 76 236 2 1 201 BoP Cash Pre-tax Taxe
Slide 15: Healthy debt structure and maturity profile, with leverage ratio of 3.6x
Healthy debt structure and maturity profile, with leverage ratio of 3.6x Debt Structure Highlights Debt by Type (%) Debt by Currency (%) Consolidated Debt: S/ 3,735 ✓ Gradually reducing leverage since the 2022 acquisition of Monterrey network and IMAT Oncomedica with 3.0x target Term Loan 32% 10% Se
Slide 16: Our immediate focus is re-engaging doctors to recover volumes in Mexico
We remain committed to advancing and transforming healthcare in SSLA “Our through our value-based care model, enhancing medical resolutions, optimizing our platform, and driving sustainable and profitable growth. immediate focus is re- Peru should remain a key contributor to Auna´s near to mid-term
Slide 17: Q&A
Q&A qund
Slide 18: Exhibits
Exhibits qund
Slide 19: Consolidated Balance Sheet
Consolidated Balance Sheet (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Mar-25 Δ Mar-25 Mar-25 Δ Mar-25 Mar-25 Dec-24 Mar-25 Dec-24 (USD) vs Dec-24 (USD) vs Dec-24 Assets Liabilities Current assets Current liabilities Cash and cash equivalents 55 201 236 (35)
Slide 20: Consolidated Statement of Income (1/2)
Consolidated Statement of Income (1/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 1Q'25 Δ 1Q'25 vs 1Q'25 1Q'24 (USD) 1Q'24 4Q'24 Revenue Healthcare Services Mexico 66 243 308 -21% -9% Healthcare Services Colombia 92 339 349 -3% -4% Healthcare Services Peru
Slide 21: Consolidated Statement of Income (2/2)
Consolidated Statement of Income (2/2) (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) 1Q'25 Δ 1Q'25 vs 1Q'25 1Q'24 (USD) 1Q'24 4Q'24 Share of profit of equity accounted investees 1 3 2 24% 21% Profit (loss) before tax 17 62 16 280% 65% Income tax expense (benef
Slide 22: Consolidated Cash Flow Statement
Consolidated Cash Flow Statement (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) YTD 25 Δ Mar-25 vs YTD 25 Δ Mar-25 vs Mar-25 Mar-24 Mar-25 Mar-24 (USD) Mar-24 (USD) Mar-24 Cash flows from operating activities Cash flows from investing activities (Loss) profit f
Slide 23: Consolidated Adjusted EBITDA and Adjusted EBITDA Margin reconciliation
Consolidated Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted EBITDA: is calculated as profit (loss) before tax for the period plus net finance cost, depreciation and amortization, pre- operating
Slide 24: Consolidated Peru Adjusted EBITDA and Adjusted EBITDA Margin reconciliation
Consolidated Peru Adjusted EBITDA and Adjusted EBITDA Margin reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Consolidated Peru Adjusted EBITDA: is calculated by adding Healthcare Services Peru Segment Adjusted EBITDA plus Oncosalud Peru Segment Ad
Slide 25: Adjusted Net Income reconciliation
Adjusted Net Income reconciliation (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Net Income: is calculated as profit (loss) for the period plus adjustments as described below. 1Q'25 1Q'25 1Q'24 4Q'24 (USD) Net Income (Loss) 10 38 (8) 24 (a) Pre-operat
Slide 26: Free Cash Flow
Free Cash Flow (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Free Cash Flow: is calculated by adding Net Cash Flows from Operations and Net Cash Flows used in Investment activities. Mar-25 Cash from Operating Activities 160 (-) Income tax 58 (+) Interest recei
Slide 27: Adjusted Basic and Diluted Earnings per Share
Adjusted Basic and Diluted Earnings per Share (Figures in millions of Soles and millions of US Dollars, unless expressed otherwise) Adjusted Basic and Diluted Earnings per Share: Adjusted Basic and Diluted Earnings per Share is calculated by dividing profit attributable to owners of Adjusted Net Inc
Slide 28: Net Debt reconciliation
Net Debt reconciliation (Figures in millions of Soles, unless expressed otherwise) Net Debt: We calculate Net Debt as Gross Debt minus Cash and cash equivalents. 2021 2022 2023 1Q'24 4Q'24 1Q'25 (+) Loans and borrowings 1,352 3,349 3,762 3,829 3,620 3,595 Short t erm debt 30 2,041 385 460 654 765 Lo
Slide 29: Leverage ratio reconciliation
Leverage ratio reconciliation (Figures in millions of Soles, unless expressed otherwise) Leverage Ratio: is calculated as (i) current and non-current loans and borrowings plus current and non-current lease liabilities minus (ii) cash and cash equivalents, divided by (iii) Last twelve months Adjusted
Slide 30: Key Operational Metrics – Oncosalud Peru & Healthcare Services
Key Operational Metrics – Oncosalud Peru & Healthcare Services 1) As of period end and as reported to the National Superintendence of Health Susalud. Δ 1Q'25 vs Includes Oncology plans and Health plans. 1Q'25 1Q'24 2) Includes active plan members and inactive members. Inactive members are defined as
Slide 31: Trends in Key Financial Metrics
Trends in Key Financial Metrics (Figures in millions of Soles, unless expressed otherwise) 1Q'23 2Q'23 3Q'23 4Q'23 1Q'24 2Q'24 3Q'24 4Q'24 1Q'25 Revenue Oncosalud Peru 221 230 237 244 253 269 273 276 281 Healthcare Services Peru 212 217 230 225 241 255 255 245 263 Healthcare Services Colombia 252 28
Slide 32: Investor Relations
Investor Relations contact@aunainvestors.com www.aunainvestors.com 32